Patients’ characteristics
| . | EUROCORD (N = 496) . | JSTCT (N = 1150) . | ||
|---|---|---|---|---|
| n∗ . | %† . | n∗ . | %† . | |
| Disease subtype | ||||
| B-cell lymphoma | 247 | 49.8 | 658 | 57.2 |
| Mature T/NK-cell lymphoma | 98 | 19.8 | 401 | 34.9 |
| Hodgkin lymphoma | 131 | 26.4 | 58 | 5.0 |
| NHL (not specified) | 20 | 4.0 | 33 | 2.9 |
| Year of transplantation | ||||
| 2000-2004 | 9 | 1.8 | 140 | 12.2 |
| 2005-2009 | 196 | 39.5 | 258 | 22.4 |
| 2010-2014 | 256 | 51.6 | 445 | 38.7 |
| 2015-2017 | 35 | 7.1 | 307 | 26.7 |
| Patient sex | ||||
| Male | 312 | 62.9 | 695 | 60.4 |
| Female | 183 | 36.9 | 455 | 39.6 |
| Missing | 1 | 0.2 | 0 | 0.0 |
| Age at CBT | 46 (IQR, 32-56) | 53 (IQR, 42-60) | ||
| Age‡ (<50 or ≥50) | ||||
| 18-49 | 302 | 60.9 | 471 | 41.0 |
| 50-70 | 194 | 39.1 | 679 | 59.0 |
| KPS | ||||
| 40-80 | 90 | 18.1 | 368 | 32.0 |
| 90-100 | 278 | 56.0 | 694 | 60.3 |
| Missing | 128 | 25.8 | 88 | 7.7 |
| rDRI | ||||
| Low | 208 | 41.9 | 84 | 7.3 |
| Intermediate | 191 | 38.5 | 458 | 39.8 |
| High-very high | 68 | 13.7 | 567 | 49.3 |
| Missing | 29 | 5.8 | 41 | 3.6 |
| History of auto-HCT | ||||
| No | 223 | 45.0 | 842 | 73.2 |
| Yes | 273 | 55.0 | 308 | 26.8 |
| Double or single | ||||
| Single | 192 | 38.7 | 1150 | 100.0 |
| Double | 304 | 61.3 | 0 | 0.0 |
| TNCs at collection per recipient weight (×107/kg) | 4.38 (IQR, 3.69-5.35)§ | 2.66 (IQR, 2.27-3.17) | ||
| Number of CD34+ cells at collection per recipient weight (×105/kg) | 1.76 (IQR, 1.19-2.51)| | 0.81 (IQR, 0.60-1.15) | ||
| Number of HLA-MM | ||||
| 0-1 | 122 | 24.6 | 214 | 18.6 |
| 2- | 307 | 61.9 | 817 | 71.0 |
| Missing | 67 | 13.5 | 119 | 10.3 |
| Conditioning | ||||
| MAC | ||||
| Non-TBI | 53 | 10.7 | 92 | 8.0 |
| TBI | 38 | 7.7 | 280 | 24.3 |
| Missing | 13 | 2.6 | 0 | 0.0 |
| RIC | ||||
| Non-TBI | 83 | 16.7 | 175 | 15.2 |
| TBI | 301 | 60.7 | 602 | 52.3 |
| Missing | 8 | 1.6 | 1 | 0.1 |
| GVHD prophylaxis | ||||
| CI + MMF | 359 | 72.4 | 320 | 27.8 |
| CI + MTX | NA | NA | 529 | 46.0 |
| CI + steroid | 62 | 12.5 | NA | NA |
| Others | 75 | 15.1 | 301 | 26.2 |
| Use of ATG | ||||
| No | 279 | 56.3 | 1067 | 92.8 |
| Yes | 151 | 30.4 | 3 | 0.3 |
| Missing | 66 | 13.3 | 80 | 7.0 |
| Patient CMV status | ||||
| Positive | 206 | 41.5 | 848 | 73.7 |
| Negative | 269 | 54.2 | 200 | 17.4 |
| Missing/not performed | 21 | 4.2 | 102 | 8.9 |
| . | EUROCORD (N = 496) . | JSTCT (N = 1150) . | ||
|---|---|---|---|---|
| n∗ . | %† . | n∗ . | %† . | |
| Disease subtype | ||||
| B-cell lymphoma | 247 | 49.8 | 658 | 57.2 |
| Mature T/NK-cell lymphoma | 98 | 19.8 | 401 | 34.9 |
| Hodgkin lymphoma | 131 | 26.4 | 58 | 5.0 |
| NHL (not specified) | 20 | 4.0 | 33 | 2.9 |
| Year of transplantation | ||||
| 2000-2004 | 9 | 1.8 | 140 | 12.2 |
| 2005-2009 | 196 | 39.5 | 258 | 22.4 |
| 2010-2014 | 256 | 51.6 | 445 | 38.7 |
| 2015-2017 | 35 | 7.1 | 307 | 26.7 |
| Patient sex | ||||
| Male | 312 | 62.9 | 695 | 60.4 |
| Female | 183 | 36.9 | 455 | 39.6 |
| Missing | 1 | 0.2 | 0 | 0.0 |
| Age at CBT | 46 (IQR, 32-56) | 53 (IQR, 42-60) | ||
| Age‡ (<50 or ≥50) | ||||
| 18-49 | 302 | 60.9 | 471 | 41.0 |
| 50-70 | 194 | 39.1 | 679 | 59.0 |
| KPS | ||||
| 40-80 | 90 | 18.1 | 368 | 32.0 |
| 90-100 | 278 | 56.0 | 694 | 60.3 |
| Missing | 128 | 25.8 | 88 | 7.7 |
| rDRI | ||||
| Low | 208 | 41.9 | 84 | 7.3 |
| Intermediate | 191 | 38.5 | 458 | 39.8 |
| High-very high | 68 | 13.7 | 567 | 49.3 |
| Missing | 29 | 5.8 | 41 | 3.6 |
| History of auto-HCT | ||||
| No | 223 | 45.0 | 842 | 73.2 |
| Yes | 273 | 55.0 | 308 | 26.8 |
| Double or single | ||||
| Single | 192 | 38.7 | 1150 | 100.0 |
| Double | 304 | 61.3 | 0 | 0.0 |
| TNCs at collection per recipient weight (×107/kg) | 4.38 (IQR, 3.69-5.35)§ | 2.66 (IQR, 2.27-3.17) | ||
| Number of CD34+ cells at collection per recipient weight (×105/kg) | 1.76 (IQR, 1.19-2.51)| | 0.81 (IQR, 0.60-1.15) | ||
| Number of HLA-MM | ||||
| 0-1 | 122 | 24.6 | 214 | 18.6 |
| 2- | 307 | 61.9 | 817 | 71.0 |
| Missing | 67 | 13.5 | 119 | 10.3 |
| Conditioning | ||||
| MAC | ||||
| Non-TBI | 53 | 10.7 | 92 | 8.0 |
| TBI | 38 | 7.7 | 280 | 24.3 |
| Missing | 13 | 2.6 | 0 | 0.0 |
| RIC | ||||
| Non-TBI | 83 | 16.7 | 175 | 15.2 |
| TBI | 301 | 60.7 | 602 | 52.3 |
| Missing | 8 | 1.6 | 1 | 0.1 |
| GVHD prophylaxis | ||||
| CI + MMF | 359 | 72.4 | 320 | 27.8 |
| CI + MTX | NA | NA | 529 | 46.0 |
| CI + steroid | 62 | 12.5 | NA | NA |
| Others | 75 | 15.1 | 301 | 26.2 |
| Use of ATG | ||||
| No | 279 | 56.3 | 1067 | 92.8 |
| Yes | 151 | 30.4 | 3 | 0.3 |
| Missing | 66 | 13.3 | 80 | 7.0 |
| Patient CMV status | ||||
| Positive | 206 | 41.5 | 848 | 73.7 |
| Negative | 269 | 54.2 | 200 | 17.4 |
| Missing/not performed | 21 | 4.2 | 102 | 8.9 |
auto-HCT, autologous HCT; CMV, human cytomegalovirus; dCBT, transplantation using double CB units; HLA-MM, HLA mismatches; KPS, Karnofsky Performance Status; NA, not available; NHL, non-Hodgkin lymphoma; sCBT, transplantation using single CB unit.
n indicates the number of patients with each characteristics.
% indicates the percentage of patients in each group.
Indicates patients' age at CBT.
sCBT: 3.76 (IQR: 3.70-5.24), dCBT: 4.94 (IQR: 3.70-5.34).
sCBT: 1.51 (IQR: 1.19-2.50), dCBT: 1.88 (IQR: 1.20-2.51).